Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1497)	5/21/2004 3:15:20 AM
From: Icebrg	Read Replies (2) \| Respond to of 1826

MGI Pharma "outperform" Thursday, May 20, 2004 10:14:26 AM ET Robert W. Baird NEW YORK, May 20 (New Ratings) - Analysts at Robert W Baird reiterate their "outperform" rating on MGI Pharma Inc (MOGN.NAS). The target price is set to $69. In a research note published this morning, the analysts mention that the company's product, Aloxi, is expected to witness robust sales momentum in the forthcoming quarters. A recent survey conducted by Cancer Consultants Inc on practicing community oncologists supports this stance, the analysts say. The analysts expect the company to turn profitable by mid 2004.